Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NOD1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NOD1 Recombinant Protein (CARD Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View NOD1 Products |
| Gene Delivery | NOD1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View NOD1 Products |
| Benchmark Ab | Anti-NOD1 Recombinant Antibody Recombinant positive control for assay validation. |
View NOD1 Products |
| Validator | NOD1 siRNA Set For knockdown verification in functional assays. |
View NOD1 Products |
| Related Target A | NOD2 Homologous intracellular PRR; critical counter-screening target to ensure selectivity. |
View NOD2 Products |
| Related Target B | RIPK2 Direct downstream kinase partner in the NOD1 signaling cascade; major therapeutic co-target. |
View RIPK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against NOD2 homolog | High-purity recombinant NOD1 and NOD2 proteins strictly verified by mass spectrometry. |
| Intracellular target screening limitations | High-titer Lentivirus for establishing stable reporter cell lines (NF-kB/MAPK pathways). |
| Lack of reliable positive controls | Sequence-verified clinical benchmark recombinant antibodies included in portfolio. |
| Off-target assay noise | Sequence-verified, endotoxin-controlled reagents to minimize non-specific immune activation. |
Live NOD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NOD1 therapeutics is intensifying, with major players shifting focus from systemic anti-inflammatory approaches to localized mucosal immunology and oncology adjuvants. As first-generation small molecule inhibitors enter preclinical and early clinical validation, the next wave of R&D is targeting highly selective, tissue-restricted NOD1 modulators to avoid systemic immunosuppression while maximizing therapeutic efficacy in diseases like inflammatory bowel disease (IBD) and specific solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | GlaxoSmithKline, academic consortia | Inflammatory Bowel Disease (IBD), Asthma | In vitro binding & selectivity assays (Need NOD1 vs NOD2 recombinant proteins) |
| Small Molecule Agonist | Oncology-focused biotechs | Cancer Immunotherapy (Adjuvant) | Cell-based reporter assays (Need NOD1 lentivirus for stable cell line construction) |
| PROTAC / Degrader | Targeted protein degradation players | Autoimmune disorders, Chronic inflammation | Target abundance validation (Need validated siRNA and high-specificity antibodies) |